Fate Therapeutics (FATE) Capital Expenditures (2012 - 2026)
Fate Therapeutics (FATE) posted Capital Expenditures of $239000.0 for Q1 2026, down 95.7% on a QoQ basis from $5.6 million in Q4 2025, and down 63.51% year-over-year from $655000.0 in Q1 2025.
Fate Therapeutics (FATE) Capital Expenditures (2012 - 2026) Analysis & Trends
Fate Therapeutics' Capital Expenditures history runs 15 years deep, the most recent figure standing at $239000.0 for Q1 2026.
- Quarterly Capital Expenditures fell 63.51% year-over-year to $239000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 608.96% YoY) and the FY2025 annual result came in at $6.0 million, up 4152.14% from the prior year.
- Capital Expenditures was $239000.0 for Q1 2026 at Fate Therapeutics, down from $5.6 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $16.8 million in Q2 2022 and bottomed at -$27.8 million in Q4 2022.
- A 5-year average of $796470.6 and a median of $338000.0 in 2025 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 4578.57% in 2025, while the deepest fall reached 391.74% in 2025.
- Fate Therapeutics' Capital Expenditures stood at -$27.8 million in 2022, then surged by 121.5% to $6.0 million in 2023, then plunged by 97.93% to $124000.0 in 2024, then surged by 4379.84% to $5.6 million in 2025, then plunged by 95.7% to $239000.0 in 2026.
- Business Quant data shows FATE's Capital Expenditures at $239000.0 in Q1 2026, $5.6 million in Q4 2025, and -$595000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - | 239,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 239,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Dec 31, 2025 | 5.56 Mn |
| Dec 31, 2025 | 5.56 Mn |
| Sep 30, 2025 | -595,000.00 |
| Sep 30, 2025 | -595,000.00 |
| Jun 30, 2025 | 338,000.00 |
| Jun 30, 2025 | 338,000.00 |
| Mar 31, 2025 | 655,000.00 |
| Mar 31, 2025 | 655,000.00 |
| Dec 31, 2024 | 124,000.00 |
| Dec 31, 2024 | 124,000.00 |
| Sep 30, 2024 | -121,000.00 |
| Sep 30, 2024 | -121,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Jun 30, 2024 | 123,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Dec 31, 2023 | 5.99 Mn |
| Dec 31, 2023 | 5.99 Mn |